A Study of Saquinavir Soft Gelatin Capsules Plus Zidovudine Plus Lamivudine in the Treatment of HIV-1 Infected Patients Who Have Never Taken Anti-HIV Drugs
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Hoffmann-La Roche
All enrolled patients will receive the following 3 drug combination: Saquinavir, Zidovudine and Lamivudine. Efficacy and duration of anti-viral response will be evaluated by monitoring of HIV-1 RNA levels. Patients below the detectable limit of 200 copies/ml will be analyzed using the Ultra-direct method with a detection limit of 20 copies/ml. CD4 and CD8 cell counts will also be analyzed.
Age
16–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Patients must have:
Plasma HIV-1 RNA titers \> 10,000 copies/ml.
CD4 cell count \> 100 cells/mm3.
You may not be if
Co-existing Condition:
Patients with any of the following conditions will be excluded:
Any prior anti-retroviral drug therapy.
Prior Medication:
Excluded:
Previous anti-retroviral drug therapy.
Clareo Health | A Study of Saquinavir Soft Gelatin Capsules Plus Zidovudine Plus Lamivudine in the Treatment of HIV-1 Infected Patients Who Have Never Taken Anti-HIV Drugs
